Sanara MedTech Q3 revenue +22% to $26.3M; net income from continuing ops positive; THP discontinued

Sanara MedTech Inc.

2025-Q3 EPS reported -$4.04 vs consensus -$0.22 ▼ miss (-1742.2%)

Q3 net revenue $26.3M (+22% YoY); net income from continuing ops $0.8M vs loss $0.2M; Adj. EBITDA $4.9M (+$2.3M).
Soft tissue repair revenue +24% driven by CellerateRX and BIASURGE; gross margin improved to 93% from 91%.
Operations of Tissue Health Plus (THP) ceased in Q3; $26.5M noncash impairment charge; THP classified as discontinued ops.
Net loss from discontinued ops $31.2M in Q3; overall net loss $30.4M vs $2.9M loss YoY from continuing and disc ops.
Seth Yon appointed CEO effective Sept 15, 2025; Ron Nixon remains Executive Chairman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.